The traditional concept of the IL-23/IL-17 axis in inflammatory diseases, such as spondyloarthritis, psoriasis and inflammatory bowel disease, is that myeloid cell-derived IL-23 engages its receptor expressed by adaptive and innate-like lymphocytes [2]. This evidence concerns the gene IL23A and inflammatory bowel disease.